2019
DOI: 10.1016/j.thromres.2019.07.007
|View full text |Cite
|
Sign up to set email alerts
|

The role of anticoagulation in venous thromboembolism primary prophylaxis in patients with malignancy: A systematic review and meta-analysis of randomized controlled trials

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
6
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 40 publications
1
6
0
1
Order By: Relevance
“…There may be, however, a role for these medications in the primary TPX. A meta-analysis of randomized controlled trials investigating the use of NOACs in a total of 13,338 cancer patients for primary TPX has revealed that NOACs are effective in VTE prevention and does not increase the risk of major bleeding compared to placebo [42], although a subgroup analysis of advanced cancer patients has not been performed. Although non-invasiveness and no need for monitoring would make NOACs convenient for use in palliative care and hospice, the actual use may be limited in this setting due to decreased oral intake.…”
Section: Thromboprophylaxis Agent Selectionmentioning
confidence: 99%
“…There may be, however, a role for these medications in the primary TPX. A meta-analysis of randomized controlled trials investigating the use of NOACs in a total of 13,338 cancer patients for primary TPX has revealed that NOACs are effective in VTE prevention and does not increase the risk of major bleeding compared to placebo [42], although a subgroup analysis of advanced cancer patients has not been performed. Although non-invasiveness and no need for monitoring would make NOACs convenient for use in palliative care and hospice, the actual use may be limited in this setting due to decreased oral intake.…”
Section: Thromboprophylaxis Agent Selectionmentioning
confidence: 99%
“…There were some published studies evaluating new oral anticoagulants, including dabigatran, rivaroxaban, edoxaban, and apixaban, for patients with cancerassociated VTE. [25][26][27][28][29][30] Most of them included both RCTs and prospective cohort studies and came to the conclusion that new oral anticoagulants seem to be as effective and safe as conventional treatment for the prevention of VTE in patients with cancer. Later, studies about specific oral anticoagulants, rivaroxaban, have also emerged.…”
Section: Discussionmentioning
confidence: 99%
“…Indeed, at the general population level, incidence rates for venous thromboembolism (VTE) approximate one to two cases per 1000 people/year, while cancer patients generally show a 4 to times greater risk [2]. Consistently, VTE is associated with poor prognosis of disease in glioblastoma, ovarian, colorectal, lung and pancreatic cancer [3][4][5]. In strict regard to breast cancer, data are available in support of the prognostic relevance of coagulation activation on survival in both advanced and early disease [6].…”
Section: Introductionmentioning
confidence: 99%